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Introduction
!
The presence of multiple serrated polyps in pa-
tients is associated with an increased risk of colo-
rectal cancer (CRC). Since the recognition of this
association, it has become clear that both serrated
polyposis patients and their first-degree relatives
have an increased risk of CRC [1,2]. The so-called
serrated polyposis syndrome (SPS) is now recog-
nised as one of the new polyposis syndromes.
Since no genetic basis for SPS has been discovered
thus far, diagnosis is based on clinical criteria de-
fined by the World Health Organization (WHO)
[3]. The latest WHO definition for SPS dates from
2010 and states that patients fulfill the criteria if
they have at least 5 serrated polyps proximal to
the sigmoid colon, of which two are at least 10
mm; or any number of serrated polyps proximal
to the sigmoid colon in an individual who has a
first-degree relative with SPS; or at least 20
serrated polyps of any size distributed through-
out the colon. In comparison with the previous
criteria published in 2000, polyps with a serrated
architecture apart from hyperplastic polyps are
also included in the definition. In addition, the
third criterion has been made less stringent, re-
ducing the required serrated polyps count from
30 to 20 [4].
Since the number of colorectal screening pro-
grams is increasing worldwide, an up-to-date es-
timate of the prevalence of SPS is necessary to
predict the number of SPS cases that may be iden-
tified in (differently organized) screening pro-
grams. As the diagnosis of SPS is often missed in
daily practice, a prevalence estimate can be used
to check whether there is optimal recognition of
the syndrome by clinicians [5,6]. In addition,
identification of SPS patients through screening
programs can provide valuable information on
CRC risk and prognosis as this patient population
is not biased towards a more severe phenotype,
which is the major problem in the cohorts of SPS
patients that present to genetics clinics [7].
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Background and study aims: The most frequently
cited prevalence for serrated polyposis syndrome
(SPS) is 1 in every 3000 people screened, but this
value is debated. Additionally, changes in 2010 in
the World Health Organization (WHO) diagnostic
criteria for SPS might affect reported prevalence.
An updated estimate of SPS prevalence is neces-
sary to predict the number of cases in screening
programs.
Patients and methods: A systematic literature
search was conducted in the PubMed, EMBASE,
and Web of Science databases up to February
2014.Studies reporting the prevalence of SPS, as
defined by WHO criteria, in screening popula-
tions were selected.
Results: Six studies reported prevalence of SPS in
screening populations, varying from 0 to 0.66%.
The highest prevalences (0.34% and 0.66%) were
seen in studies from screening programs with pa-
tients pre-selected by fecal blood test. Primary co-
lonoscopy-based screening programs, that have
the lowest risk of bias, reported SPS prevalences
ranging from 0 to 0.09%. Across studies, 56 pa-
tients were diagnosed with SPS of whom 3 pres-
ented with synchronous colorectal cancer at in-
dex endoscopy.
Conclusion: The true prevalence of SPS is unclear
because of the risk of bias across studies, but is
likely to be below 0.09% as derived from primary
colonoscopy screening programs. The prevalence
in pre-selected screening populations after posi-
tive fecal testing is higher, with reported values
of 0.34% and 0.66%. Large and high quality pri-
mary colonoscopy screening studies, reporting
SPS prevalence in adequately described popula-
tions, are necessary for better estimation of the
true prevalence of SPS in average-risk patients.
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The prevalence of SPS is not clear at present. The most frequently
cited prevalence for SPS is 1 patient in every 3000 people
screened by sigmoidoscopy, but this number is debated as it is
based on an abstract from 2001 with limited information on
study procedures [8]. The amendment of the WHO criteria in
2010 is likely to influence prevalence numbers because less strin-
gent criteria and new endoscopy techniques might lead to an in-
crease in the number of cases that fulfill the criteria. No systema-
tic discussion on the prevalence of SPS is available so far. There-
fore we attempted to estimate the prevalence of SPS and the
associated CRC occurrence, as defined by the previous and the
new WHO criteria, in a systematic review that includes studies
investigating SPS prevalence in screening populations.
Methods
!
Data sources and search
A systematic search was conducted in the electronic databases
PubMed, EMBASE and Web of Science through February 2014
with the aid of a librarian. The Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) checklist was used for all the
steps reported in this review [9]. The full search strategy is pres-
ented in Appendix e1 (available online). No restrictions regarding
language, year of publication, or publication type were imposed.
Additional studies were sought by scanning the reference lists of
included articles, reviews, and key textbooks and by searching
Google Scholar. If more than one article was published from a
study, the version that provided the most updated data was se-
lected for inclusion. Additional information was extracted from
all articles concerning the screening program. Conference ab-
stracts and letters to the editor were included only if no full-text
article presenting the same data was available.
Two independent authors (M. V. and Y. H.) assessed the studies
by title and abstract to judge whether inclusion criteria were
met. Case reports and reviews were excluded as these contain
no primary epidemiological data. Subsequently, the full text of
potentially eligible studies was independently examined by two
authors (M. V. and Y. H.), and articles presenting prevalence rates
of SPS as defined by the WHO criteria in screening populations
were included. Disagreements were resolved after discussion
with a third author (T. B.).
Data extraction and quality assessment
Two authors (M. V. and Y. H.) independently evaluated and ex-
tracted background characteristics and outcomes from the in-
cluded studies. The study characteristics extracted included: first
author, year of publication, place of research, and time period,
and also methods of inclusion and exclusion and study design to
evaluate the generalizability of the source population.
To evaluate the study process and population numbers, we asses-
sed the number of patients approached from the source popula-
tion, the reporting of responders and nonresponders, the number
of patients undergoing colonoscopy or other screening tests, and
the number of patients diagnosed with SPS.Critical appraisal of
the studies was done using a methodological scoring system for
prevalence and incidence studies as previously described [10].
Quality items evaluated were: methods of sampling, sampling
frame, sample size, outcomemeasurement, outcome assessment,
response rate, statistical reporting, and interpretation of study
results [10].
Adequate sample size was calculated ([N=Z2α/2×p(1–p)]/d2;
where N is the sample size, Zα/2 (1.96) is the z value for 95% con-
fidence, p the expected prevalence, and d the accuracy of the es-
timation) based on an estimated prevalence of 0.09% and an ac-
curacy of 0.005%. This gave a minimum sample size of approxi-
mately 1380000, which would be considered adequate in the
quality assessment.
Disagreements regarding data extraction and quality assessment
were resolved by discussion and consensus with a third reviewer
(T.B.).
Data synthesis and analysis
The primary outcome of the study was the prevalence of SPS as
defined by the WHO criteria in screening populations. Studies
were grouped and analyzed based on the screening method
used and the criteria used for diagnosis (WHO 2000 or WHO
2010). For point estimates of prevalence, 95% confidence inter-
vals (95%CI) were estimated. Prevalence numbers were present-
ed using Graphpad Prism (Version 5.03 for Windows, GraphPad
Software, San Diego California USA).
Results
!
Study selection
Our search, described in●" Fig. 1, resulted in 2476 unique cita-
tions. After exclusion of 2356 articles, based on title and abstract,
we evaluated the full text of the remaining 120 citations that
were considered potentially relevant. One study, an abstract
from 1994, was discarded because the full text was unavailable
to us despite extensive searching. A total of 113 studies were ex-
cluded because no SPS prevalence rates were presented. Six stud-
ies described the prevalence rates of SPS defined by the old or
new WHO criteria in screening populations and were included
for analysis. One article included two databases with screened
patients from different origins. We excluded the second, smaller
database because the patients were included in a randomized
controlled trial instead of being randomly selected for screening
and this could lead to potential selection bias [11].
Study characteristics
Six studies were selected for the review, three prospective and
three retrospective by nature. Of the included studies, two were
described in full-text articles [11,12], two in conference ab-
stracts [8,13] and two in letters to the editor [14,15]. Character-
istics of the studies and their source populations are presented
in●" Table1. In four studies, patients were diagnosed with SPS
as defined by the most recent WHO criteria [11,12,14,15]. In
the other two studies the criteria of 2000 were used [8,13]. In
two studies the second WHO criterion, based on a positive fam-
ily history for SPS, was not used for diagnosis [12,14], in the re-
maining studies it was not reported whether this criterion was
systematically assessed.
In three studies, before colonoscopy, participants had undergone
an initial screening test prior to inclusion in the study. In two of
these the screening method was fecal testing [14,15]. The study
of Biswas et al. [14] included only persons who underwent a co-
lonoscopy after positive findings from a guaiac fecal occult blood
test (gFOBT) [14], and the study of Moreira et al. [15] included
only persons with positive findings from a fecal immunochemical
test (FIT). In these studies, with data from 2009 to 2012, the num-
ber of persons participating in the screening programwas not re-
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ported; thus it was impossible to calculate response rates and
compare responders and nonresponders. The prevalence of SPS
could only be calculated for those persons with a positive stool
test, namely 755 (Biswas et al. [14]) and 2355 (Moreira et al.
[15]). In the third study, by Lockett et al., 57254 persons between
55 and 64 years of age were invited for sigmoidoscopy screening
between 1994 and 1999 [8,17]. All participants underwent flex-
ible sigmoidoscopy andwere referred for colonoscopy if theymet
any of the high risk criteria: adenoma 1cm or larger; three or
more adenomas; tubulovillous or villous histology; severe dys-
plasia or malignant disease; or 20 or more hyperplastic polyps
proximal to the distal rectum. Although participants who did
not fulfill these criteria were not further investigated, the preval-
ence was calculated on the total screening population leading to
results with a high risk of bias [8].
The remaining three studies selected participants for colonosco-
py-based screening, although the target population differed be-
tween studies [11–13]. The study of Orlowska et al. included
two categories of people between 2000 and 2004.The majority
(85.8%) were aged 50–66 years and originated from a national
screening program for CRC [13]; in addition, people aged 40–49
years were also included in the screening program if they had a
family history of cancer of any type. In the study by Kahi et al.,
average-risk patients were included if they were 50 years or old-
er and presented for first-time screening colonoscopy between
2000 and 2009 [11]. The analysis of SPS prevalence included
only the patients screened by the endoscopist with the highest
detection rate; this was a subset of 3170 from the total of 6681
patients. In the study by Hazewinkel et al., 6600 screening-naïve
individuals aged 50–75 years were randomly selected from the
population and invited to undergo a primary screening colonos-
copy, between 2009 and 2010 [12]. The inclusion and exclusion
criteria are reported fully in●" Table 1.
Risk of bias within studies
Scores for quality items of the included articles are presented in
●" Table 2. In four of the studies, the study design used a method
of sampling to assemble the study population which was not
ideal but was mostly comparable to the general population [12–
15]. In the study by Kahi et al. [11] the route by which screening
patients presented themselves for colonoscopy was unclear, lead-
ing to a higher risk of bias. Only one study used the most desir-
able study design by randomly selecting and inviting screening-
naïve individuals for a colonoscopy-based screening program
[12]. The sample size was not adequate in any of the included
studies.
All studies used objective and standardized criteria for assessing
the presence of SPS, namely the WHO criteria of 2000 or 2010.
Only one study fully described the sociodemographic character-
istics of participants, thereby providing information on the ap-
plicability of the results [12].
●" Table 3 shows that several studies did not adequately report
the response rates of participants within the screening program,
making it impossible to compare responders and nonresponders.
It was possible to determine the response rate of two studies [8,
12], and these rates were adequate in both studies.
Overall, substantial risk of bias is likely for all included studies
(●" Table 2).
Limited information was given across studies on quality indica-
tors for colonoscopy. The study of Hazewinkel et al. [12] was the
only study reporting unadjusted cecal intubation rate (98.7%),
median withdrawal time (10 minutes), and median score (5) on
the Ottowa Bowel Preparation Scale, while Orlowska et al. only
reported cecal intubation rate (91.1%) [18]. Other studies report-
ed no information on quality of colonoscopy [8] or reported only
that colonoscopies were performed by experienced endoscopists
[11,15]. The study by Biswas et al. was conducted under the qual-
ity regulations of the UK National Health Service Bowel Cancer
Records identified through 
searching PubMed 
(n = 1265)
Records identified through 
searching EMBASE 
(n = 1937)
Records identified (n = 6084)
Studies included (n = 6)
Records screened on title 
and/or abstract (n = 2476)
Records identified through 
searching Web of Science 
(n = 2882)
Duplicates removed 
(n = 3608)
Records excluded: not regarding 
serrated/hyperplastic/
metaplastic polyposis 
syndrome (n = 2263)
Records excluded
Case report: n = 39
Review: n = 54
Full text articles assessed for 
eligibility (n = 120)
Articles not found (n = 1)
Full text articles excluded: no 
prevalence number in screening 
population (n = 113)
Fig.1 Prevalence of serrated polyposis syndrome
in screening populations: a systematic review.
Flowchart presenting the inclusion and exclusion of
studies.
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Screening Programme, with accredited endoscopists, but did not
provide detailed information on quality parameters [14,16].
Prevalence rates
The prevalence of SPS varied widely from 0% to 0.66% between
the six studies (●" Fig. 2,●" Table 3). Because only one study re-
ported the 95% confidence intervals for the prevalence estimate
[14], we estimated the 95% confidence intervals for the other
studies (●" Fig. 2).
The three studies in which patients were pre-selected for colo-
noscopy, by either sigmoidoscopy or a stool test, reported preva-
lences ranging from 0.03% to 0.66% [8,14,15]. The highest prev-
alence rates, 0.34% and 0.66%, were seen in two of these three
studies; the two studies were based on screening programs that
select patients for colonoscopy by stool test [14,15]. The size of
the included source population in the two studies was unknown
and the prevalence was calculated only in the participants with a
positive stool test.
Colonoscopy-based screening programs reported prevalence
rates ranging from 0 to 0.09% [11–13]. One of these colonosco-
py-based studies used the WHO criteria of 2000 and reported a
prevalence of 0.06% [13], compared to the prevalences of 0%
and 0.09% in the studies using the WHO 2010 criteria [11,12].
Adenomas and carcinomas
The occurrence of adenomas and carcinomas varied between
studies and was not clearly reported in some studies (●" Table 4).
The presence of adenomas at index endoscopy varied from 7% to
80% in patients with detected SPS.Overall, 3 patients presented
with synchronous CRC and SPS at index colonoscopy: only 1 pa-
tient in the population screened with sigmoidoscopy and 2 pa-
tients who had been screened with FIT [8,15].
Discussion
!
In the current study we assessed the prevalence of SPS in popula-
tion screening programs. Sincewe found only six studies, all with
considerable risk of bias and lack of follow-up data, the true
prevalence remains unclear. The prevalence of SPS in persons
undergoing primary screening colonoscopies is likely to be below
0.09%, this figure being the highest reported prevalence. The
prevalence in screening populations after pre-selection by
positive stool testing is higher, with reported values of 0.34 and
0.66% from two studies. In screening populations few patients
present with synchronous CRC at the time of SPS diagnosis.
The first important finding of this study is the quantity and qual-
ity of the available studies. The number of studies investigating
Table 3 Prevalence of serrated polyposis syndrome (SPS): patient characteristics in the included studies.
First author, year Patients invited for screening, n Participants undergoing colonoscopy, n SPS patients, n Prevalence calculation
Lockett, 2001 [8] 57 2541 2051 12 12/40674
Orlowska, 2009 [13] Unclear 50 148 28 28/50148
Kahi, 2012 [11] Not applicable 3170 3 3/3170
Hazewinkel, 2014 [12] 6600 1426 0 0/1426
Moreira, 2013 [15] Unclear 2355 8 8/2355
Biswas, 2013 [14] Unclear 755 5 5/755
1 40674 participants underwent sigmoidoscopy.
Study Estimate 95 % Cl
Lockett 0.03 0.01 – 0.05
Orlowska 0.06 0.04 – 0.08
Kahi 0.09 0 – 0.20
Hazewinkel 0 NA
Moreira 0.34 0.11 – 0.58
Biswas 0.66 0.08 – 1.24
Prevalence, %
0.0 1.00.5 1.5
Fig.2 Prevalence of serrated polyposis syndrome
(SPS) in screening programs for colorectal cancer:
sigmoidoscopy screening (Lockett); primary colo-
noscopy screening (Orlowska, Kahi, Hazewinkel);
colonoscopy after fecal testing (Moreira, Biswas).
95%CI, 95% confidence interval.
Table 4 Prevalence of adenomas and carcinomas in patients with serrated polyposis syndrome (SPS) and in the overall screening population
First author Total patients, n SPS patients SPS patients with
≥1 adenoma, n (%)
SPS patients with CRC, n (%) CRC in overall population, n (%)
Lockett [8] 40 6741 12 5 (42%) 1 (8.3%) 125 (0.3%)
Orlowska [13] 50 148 28 2 (7%) 0 (0%) 416 (0.8%)
Kahi [11] 3170 3 Not reported 0 (0%) Not reported
Hazewinkel [12] 1426 0 Not applicable Not applicable 8 (0.6%)
Moreira [15] 2355 8 3 (38%) 2 (25%) Not reported
Biswas [14] 755 5 4 (80%) 0 (0%) Not reported
1 Participants underwent sigmoidoscopy.
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the prevalence of SPS in screening populations is low and most
studies have a high risk of bias because of patient selection. Be-
cause of the essential differences between the studies, we consid-
ered that it was not appropriate to pool the data. We identified
only six studies, which precluded use of a funnel plot as this re-
quires a minimum of 10 studies [19]. To avoid missing published
or unpublished studies we used Web of Science to search for ab-
stracts presented at large conferences. In addition, references in
key textbooks and review articles were screened to identify addi-
tional reports of SPS prevalence. After this extensive search we
feel that, regarding prevalence rates of SPS, reporting within
studies is a larger problem than publication bias. The prevalence
of SPS is not the primary study outcome in two of the studies in-
cluded in our review [11,12], highlighting that more SPS preval-
ence rates could be calculated from other studies reporting on
screening cohorts. In our search we found several studies report-
ing the prevalence of serrated polyps in large screening cohorts,
but they did not report the numbers that fulfilled theWHO crite-
ria [20]. Even if SPS prevalence is not the primary outcome of
these studies, reporting this detail can lead to a better under-
standing of the burden of this polyposis syndrome. Ideally, large
and high quality primary colonoscopy screening studies will pro-
spectively report SPS prevalence in adequately described popula-
tions, so that the true prevalence of SPS in average-risk patients
can be better estimated.
We observed a large difference in the prevalence of SPS between
studies screening with colonoscopy and studies screening with
stool tests before colonoscopy. Although it seems logical that
prevalence in the latter populations would be higher, studies ex-
amining fecal occult blood tests report that their accuracy for de-
tecting serrated polyps is low [21]. An explanation might be that
SPS patients were detected because of synchronous adenomas or
carcinomas. Although the presence of adenomas was high in the
studies where a stool test was used to pre-select patients for co-
lonoscopy, the number of patients presenting with CRC was not.
It is likely that patients with SPS were missed when a stool test
was used as screening test, leading to different prevalences in
the total populations. No detailed information was available on
nonresponders from the two different screening methods, mak-
ing it impossible to compare the two groups. It is unclear wheth-
er nonresponders have a different SPS prevalence compared to
responders in the screening programs.
Although the primary outcome of screening programs is the de-
tection of CRC, few CRCs were detected in patients diagnosed
with SPS during the screening programs. With only 5.4% of
screening-identified SPS patients presenting with synchronous
CRC, we noticed a large difference compared with previously de-
scribed populations where CRC occurrence was much higher,
ranging from 16% to 39% [1,7,22,23]. This can be explained by
the differences in population and method of detection. These
previous studies were not conducted in screenees but in patients
with a family history of CRC or with symptoms suspicious of CRC.
Since these patients represent the more severe phenotypes or
have a more pronounced cancer risk within their families, they
are likely to have a higher risk of CRC. The screening participants
in the current study are older and it is likely that SPS patients
with high risk of CRC were not included because they had been
diagnosed earlier and therefore were not participating in a
screening program. Additionally, we cannot exclude that the SPS
patients detected in the included studies might develop CRC dur-
ing follow-up, since we have information only on the index colo-
noscopy. Another explanation for this difference might be that
SPS is underdiagnosed in patients with CRC or large adenomas,
as the attention of the endoscopist focuses on the major lesion
while possibly overlooking synchronous serrated polyps. This is
highly dependent on the awareness of the endoscopist with re-
gard to detection of serrated polyps and serrated polyposis syn-
drome.
Surprisingly, we found no difference in reported prevalence of
SPS between the colonoscopy-based screening program that
used the 2000 WHO criteria and those that used the 2010 crite-
ria. We expected to detect a difference in prevalence between
studies using the old and new WHO criteria, because the 2010
criteria specify fewer polyps for diagnosis and hence are fulfilled
more easily. Furthermore, new endoscopic techniques increase
detection rates for serrated polyps. On the other hand, endos-
copist awareness of the malignant potential and the discrete ap-
pearance of these polyps might be more important for their de-
tection. The differences in source population and the overall
quality of the studies could also explain why we did not detect a
difference in prevalence. Another hypothesis could be that most
patients who fulfill the third 2010 criterion of at least 20 polyps
would still have fulfilled the criterion if 30 polyps had been need-
ed.
In the execution of screening programs for CRC it is useful to be
aware of the prevalence of SPS. Two previous studies report a sig-
nificant miss rate for SPS diagnosis, citing possible reasons [5,6].
Most importantly, unawareness of the SPS criteria can be a con-
tributing factor to missing this diagnosis. Additionally, informa-
tion from previous colonoscopies, such as polyp size, location,
and histology, is not always readily available. It is important for
physicians to be aware of the SPS criteria so that they can actively
check whether the criteria might be fulfilled when previous colo-
noscopy findings are taken into account. Knowledge of the prev-
alence of this syndrome helps to give an indication of the number
of SPS patients that are likely to be detected in screening pro-
grams. Endoscopists who identify a smaller number of SPS pa-
tients than other endoscopists might benefit from additional
training in the detection of serrated polyps and the recognition
of SPS [6,24].
Important strengths of this review are that this is the first review
on this topic and that we performed an extensive search for prev-
alence data. The most important limitation is the lack of available
data as highlighted above. Additionally, sampling methods in the
included studies were not intended to discover the true preval-
ence of SPS.An important problemwithin studieswas the report-
ing of the background characteristics of the source population.
Most studies did not sufficiently report the response rates for co-
lonoscopy. Studies describing populations pre-selected with
stool tests did not describe the source population, numbers of re-
sponders and nonresponders for the stool test, and the percen-
tage of positive findings from stool tests. Another limitation was
the lack of information on quality indicators for colonoscopy,
which is an important issue in diagnosis of SPS.Cecum intubation
rate, withdrawal time and bowel preparation quality are impor-
tant because flat proximal polyps are easily missed in a polluted
colon or an incomplete colonoscopy [25]. In addition, the includ-
ed studies did not present follow-up data but only findings from
a single screening colonoscopy on which SPS diagnosis was
based. As we have outlined previously, the diagnosis of SPS can
be made on a cumulative polyp count from multiple colonosco-
pies [26]. Therefore it is likely that more patients from these
screening cohorts will fulfill the criteria during follow-up.
van Herwaarden Yasmijn J et al. Low prevalence of serrated polyposis syndrome in screening populations… Endoscopy 2015; 47: 1043–1049
Review1048
D
ow
nl
oa
de
d 
by
: R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
. C
op
yri
gh
ted
 m
ate
ria
l.
In conclusion, few studies are available on the prevalence of SPS,
therefore the actual prevalence remains uncertain. Our analysis
suggests that the prevalence of SPS found in primary screening
colonoscopies is likely to be below 0.09%, while SPS prevalence
found in patients after positive findings from a stool test is higher,
with values of 0.34% and 0.66% being found. Patients with SPS
detected through screening colonoscopy rarely present with syn-
chronous CRC. Since several countries have implemented pro-
grams screening for colorectal cancer, an up-to-date estimate of
the prevalence of SPS in different populations would be useful to
predict the number of cases in various screening programs.
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